目的 探讨复方柳菊胶囊联合利福喷丁胶囊治疗肺结核的临床疗效。方法 选取2019年3月—2020年9月在许昌市结核病防治所就诊的92例肺结核患者，按照随机数字表法将所有患者分为对照组和治疗组，每组各有46例。对照组口服利福喷丁胶囊，0.6 g/次，2次/周。治疗组在对照组基础上口服复方柳菊胶囊，5粒/次，3次/d。两组患者连续治疗6个月。观察两组的临床疗效，比较两组病灶吸收、空洞闭合、痰涂片转阴的例数以及血清中白细胞介素-1β（IL-1β）、γ-干扰素（IFN-γ）、白细胞介素-8（IL-8）水平。结果 治疗后，治疗组患者的总有效率为95.65%，对照组的总有效率为82.61%，组间比较差异有统计学意义（P<0.05）。治疗后，治疗组患者病灶吸收、空洞闭合、痰涂片转阴的例数比对照组高，差异有统计学意义（P<0.05）。治疗后，两组IL-1β、IFN-γ、IL-8水平显著降低，差异有统计学意义（P<0.05）；治疗后治疗组IL-1β、IFN-γ、IL-8水平低于对照组，差异有统计学意义（P<0.05）。结论 复方柳菊胶囊联合利福喷丁胶囊治疗肺结核疗效显著，能减轻临床体征，降低炎症反应，且安全性良好。

Objective To investigate the clinical efficacy of Compound Liuju Capsules combined with Rifapentin Capsules in treatment of pulmonary tuberculosis. Methods Patients (92 cases) with pulmonary tuberculosis in Xuchang Tuberculosis Control Institute from March 2019 to September 2020 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Rifapentin Capsules, 0.6 g/time, twice weekly. Patients in the treatment group were po administered with Compound Liuju Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and the cases of focus absorption, cavity closure, and sputum smear negative, and the serum levels of IL-1β, IFN-γ, and IL-8 in two groups were compared. Results After treatment, the total effective rate was 95.65% in the treatment group, and 82.61% in the control group, and there was significant difference between the groups (P < 0.05). After treatment, the number of focal absorption, cavity closure, and sputum smear negative in the treatment group was higher than those in the control group (P < 0.05). After treatment, the levels of IL-1β, IFN-γ, and IL-8 in two groups were significantly decreased, and the difference was statistically significant (P < 0.05). After treatment, the levels of IL-1β, IFN-γ, and IL-8 in the treatment group were lower than those in the control group, and there was significant difference between two groups (P < 0.05). Conclusion Compound Liuju Capsules combined withRifapentin Capsules is effective in treatment of pulmonary tuberculosis, can reduce clinical signs and inflammatory reaction, with good safety.

R978.3